Administered With Tirzepatide (GLP-1/GIP) For The Treatment Of Obesity
31/10/2024 11:34
Oct 31 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN COMPLETES ENROLLMENT IN PHASE 2 CLINICAL STUDY OF
BREMELANOTIDE (MC4R AGONIST) CO-ADMINISTERED WITH TIRZEPATIDE
(GLP-1/GIP) FOR THE TREATMENT OF OBESITY
* PALATIN TECHNOLOGIES INC - TOPLINE RESULTS EXPECTED IN 1Q
2025
Source text: ID:nPn6FjbR0a
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity